Analysis of interleukin-13 receptor α2 expression in human pediatric brain tumors

Cancer

Volumn 101, Issue 5, 2004, Pages 1036-1042

  Kawakami, Mariko ^a   Kawakami, Koji ^a   Takahashi, Satoru ^b   Abe, Masato ^c   Puri, Raj K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

In situ expression; Interleukin 13 receptor; Pediatric brain tumor; Receptor subunits

Indexed keywords

INTERLEUKIN 13 ALPHA2 RECEPTOR; INTERLEUKIN 13 RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; BRAIN SLICE; CANCER GRADING; CANCER THERAPY; CHILD; CHILDHOOD CANCER; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TARGETING; EPENDYMOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; EPENDYMOMA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; INFANT; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; MALE; MEDULLOBLASTOMA; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-13; RECEPTORS, INTERLEUKIN-4; RNA PROBES;

EID: 4143080435     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20470     Document Type: Article

References (31)

1. Cohen KJ, Broniscer A, Glod J. Pediatric glial tumors. Curr Treat Options Oncol. 2001;2:529-536.
2. Kawakami K, Kawakami M, Puri RK. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol. 2001;21:299-310.
3. Kawakami K, Puri RK. Interleukin-13 and cancer. In: Brombacher F, editor. Interleukin-13. Georgetown, TX: Landes Bioscience, 2003:65-78.
4. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Binger DD. Tumor antigens in astrocytic gliomas. Glia. 1995;15:244-256.
5. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med. 1997;3:1362-1368.
6. Yamamoto M, Sawaya R, Mohanam S, et al. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res. 1994;15:5016-5020.
7. Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A, Hall WA. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst. 2002;94:597-606.
8. Puri RK, Leland P, Kreitman RJ, Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL-4 Pseudomonas exotoxin chimeric protein. Int J Cancer. 1994;58:574-581.
9. Puri RK, Hoon DS, Leland P, et al. Preclinical development of a recombinant toxin containing circularly permutated interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res. 1996;56:5631-5637.
10. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells over-express receptor for IL-13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 Pseudomonas exotoxin. Clin Cancer Res. 1995;1:1253-1258.
11. Debinski W, Hulet S, Connor J, Powers SK, Gillespie GY, Puri RK. Receptor for IL-13 does not interact with IL-4 but receptor for IL-4 interacts with IL-13 on human glioma cells. J Biol Chem. 1996;271:22428-22433.
12. Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor a chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 2000;60:1168-1172.
13. Joshi BH, Leland P, Asher A, Prayson RA, Varrichio F, Puri RK. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res. 2001;61:8058-8061.
14. Kawakami K, Taguchi J, Murata T, Puri RK. The interleukin-13 receptor α2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood. 2001;97:2673-2679.
15. Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ. IL-13Rα2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res. 2002;62:1103-1109.
16. Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK. In vivo overexpression of IL-13 receptor α2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med. 2001;194:1743-1754.
17. Murata T, Obiri NI, Debinski W, Puri RK. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun. 1997;238:90-94.
18. Murata T, Obiri NI, Puri RK. Structure of and signal transduction through interleukin-4 and interleukin-13 receptors. Int J Mol Med. 1998;1:551-557.
19. Kawakami M, Leland P, Kawakami K, Puri RK. Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol Res. 2001;12:459-467.
20. Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer. 2001;92:168-175.
21. Kawakami M, Kawakami K, Puri RK. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol Cancer Ther. 2002;1:999-1007.
22. Kawakami K, Joshi BH, Puri RK. Sensitization of cancer cells to interleukin 13-Pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor α chain. Hum Gene Ther. 2000;11:1829-1835.
23. Kawakami K, Kawakami M, Joshi BH, Puri RK. Interleukin-13 receptor targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 2001;61:6194-6200.
24. Kawakami K, Kawakami M, Puri RK. Interleukin-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer. J Immunol. 2002;169:7119-7126.
25. Kawakami K, Kawakami M, Husain SR, Puri RK. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor α2 chain in vivo. Gene Ther. 2003;10:1116-1128.
26. Weingart J, Strauss LC, Grossman SA, et al. Phase I/II study: intra-tumoral infusion of IL13-PE38QQR cytotoxin for recurrent supratentorial malignant glioma. [abstract] Presented at the Seventh Annual Meeting of the Society for Neuro-Oncology, San Diego, CA, November 21-24, 2002.
27. Prados MD, Lang FF, Sherman JW, et al. Convection-enhanced delivery (CED) by positive pressure infusion for intra-tumoral and peri-tumoral administration of IL13-PE38QQR, a recombinant tumor-targeted cytotoxin in recurrent malignant glioma. [abstract] Presented at the Fifth Congress of the European Association of Neuro-Oncology, Florence, Italy, September 7-10, 2002.
28. Lang F, Kunwar S, Strauss L, et al. A clinical study of convection-enhanced delivery of IL13-PE38QQR cytotoxin pre- and post-resection of recurrent GBM. [abstract] Presented at the Seventieth Annual Meeting of the American Society of Neurological Surgeons, Chicago, IL, April 6-11, 2002.
29. Kunwar S, Prados M, Lang F, et al. Pre- and post-operative infusion of IL13-PE38QQR cytotoxin by convection-enhanced delivery (CED) in recurrent malignant glioma: a Phase I study [abstract]. Proc Am Soc Clin Oncol. 2003;22:119.
30. Panoskaltsis-Mortari A, Bucy RP. In situ hybridization with digoxigenin-labeled RNA probes: facts and artifacts. Biotechniques. 1995;18:300-307.
31. Hauptmann G. One-, two-, and three-color whole-mount in situ hybridization to Drosophila embryos. Methods. 2001;23:359-372.